Differential mutagenic, antimutagenic and cytotoxic responses induced by apomorphine and its oxidation product, 8-oxo-apomorphine-semiquinone, in bacteria and yeast

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 539, Issue 1-2, 2003, Pages 29-41

  Picada, Jaqueline N ^a,b   Maris, Angel F ^c   Ckless, Karina ^c   Salvador, Mirian ^d   Khromov Borisov, Nikita N ^e   Henriques, João Antonio Pêgas ^a  

^a Centro de Biotecnologia   (Brazil)

^b UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^c FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^d UNIVERSITY OF CAXIAS DO SUL   (Brazil)

^e ST PETERSBURG STATE UNIVERSITY   (Russian Federation)

Author keywords

Ames Salmonella microsome assay; Antimutagenicity; Apomorphine; Mutagenicity; Oxidative stress; Yeast

Indexed keywords

8 OXO APOMORPHINE SEMIQUINONE; ANTIMUTAGENIC AGENT; APOMORPHINE; HYDROGEN PEROXIDE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

AMES TEST; ANTIOXIDANT ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM; BIOASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG CONJUGATION; DRUG OXIDATION; DRUG SAFETY; DRUG SCREENING; ESCHERICHIA COLI; FRAMESHIFT MUTATION; GENOTOXICITY; MUTAGEN TESTING; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SALMONELLA TYPHIMURIUM; YEAST;

SACCHAROMYCES; SACCHAROMYCES CEREVISIAE; SALMONELLA; SALMONELLA TYPHIMURIUM;

EID: 0041887199     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5718(03)00132-3     Document Type: Article

References (36)

1. Sit S.Y. Dopamine agonists in the treatment of Parkinson's disease - past, present and future. Curr. Pharm. Des. 6:2000;1211-1248.
2. Deleu D., Northway M.G., Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin. Pharmacokinet. 41:2002;261-309.
3. Dula E., Keating W., Siami P.F., Edmonds A., O'Neil J., Buttler S. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. Urology. 56:2000;130-135.
4. Cheng H.-Y., Strope E., Adams R.N. Electrochemical studies of the oxidation pathways of apomorphine. Anal. Chem. 51:1979;2243-2246.
5. Garrido J.M.P.J., Delerue-Matos C., Borges M.F.M., Macedo T.R.A., Oliveira-Brett A.M. Oxidative behaviour of apomorphine and its metabolites. Bioelectrochemistry. 55:2002;113-114.
6. Ubeda A., Montesinos C., Payá M., Alcaraz M.J. Iron-reducing and free radical scavenging properties of apomorphine and some related benzylisoquinolines. Free Radic. Biol. Med. 15:1993;159-167.
7. Gassen M., Glinka Y., Pinchasi B., Youdim M.B.H. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 308:1996;219-225.
8. El-Bachá R.S., Netter P., Minn A. Mechanisms of apomorphine cytoxicity towards rat glioma C6 cells: protection by bovine serum albumin and formation of apomorphine-protein conjugates. Neurosci. Lett. 263:1999;25-28.
9. El-Bachá R.S., Daval J.-L., Koziel V., Netter P., Minn A. Toxic effects of apomorphine on rat cultured neurons and glial C6 cells, and protection with antioxidants. Biochem. Pharmacol. 66:2001;73-85.
10. Suter W., Matter-Jaeger I. Genotoxicity of apomorphine and various catecholamines in the Salmonella mutagenicity (Ames test) and in tests for primary DNA damage using repair-deficient B. subtilis strains (Rec assay). Mutat. Res. 137:1984;17-28.
11. Tadaki S., Nozaka T., Yamada S., Ishino M., Morimoto I., Tanaka A., Kunitomo J. Clastogenicity of aporphine alkaloids in vitro. J. Pharmacobio-Dyn. 15:1992;501-512.
12. Khromov-Borisov N.N., Picada J.N., Henriques J.A.P. Dose finding in the Ames Salmonella assay. Mutat. Res. 453:2000;35-44.
13. Maron D.M., Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113:1983;173-215.
14. Mortelmans K., Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutat. Res. 455:2000;29-60.
15. Blanco M., Urios A., Martínez A. New Escherichia coli WP2 tester strains highly sensitive to reversion by oxidative mutagens. Mutat. Res. 413:1998;95-101.
16. + parent WP2 uvrA/pKM101: detection of 31 oxidative mutagens. Mutat. Res. 467:2000;41-53.
17. Maris A.F., Kern A.L., Picada J.N., Boccardi F., Brendel M., Henriques J.A.P. Gluthatione, but not transcription factor Yap1, is required for carbon source-dependent resistance to oxidative stress in Saccharomyces cerevisiae. Curr. Genet. 37:2000;175-182.
18. Maris A.F., Assumpção A.L.K., Bonatto D., Brendel M., Henriques J.A.P. Diauxic shift-induced stress resistance against hydroperoxides in Saccharomyces cerevisiae is not an adaptive stress response and does not depend on functional mitochondria. Curr. Genet. 39:2001;137-149.
19. Pungartnik C., Picada J.N., Brendel M.B., Henriques J.A.P. Further phenotypic characterization of pso mutants of Saccharomyces cerevisiae with respect to DNA repair and response to oxidative stress. Gen. Mol. Res. 1:2002;79-89.
20. L. Myers, N. Adams, L. Kier, T.K. Rao, B. Shaw, L. Williams, Microcomputer software for data management and statistical analysis of the Ames/Salmonella test. In: D. Krewski, C.A. Franklin (Eds.), Statistics in Toxicology, Gordon and Breach, New York, 1991, pp. 265-279.
21. Picada J.N., da Silva K.V.C.L., Erdtmann B., Henriques A.T., Henriques J.A.P. Genotoxic effects of structurally related β-carboline alkaloids. Mutat. Res. 379:1997;135-149.
22. Kalyanaraman B. Characterization of o-quinone radicals in biological systems. Methods Enzymol. 186:1990;333-343.
23. Mortelmans K., Riccio E.S. The bacterial tryptophan reverse mutation assay with Escherichia coli WP2. Mutat. Res. 455:2000;61-69.
24. Gruenblatt E., Mandel S., Maor G., Youdim M.B.H. Effects of R- and S-apomorphine on MPTP-induced nigrostriatal dopamine neuronal loss. J. Neurochem. 77:2001;146-156.
25. Gassen M., Gross A., Youdim M.B.H. Apomorphine, a dopamine receptor agonist with remarkable antioxidant and cytoprotective properties. Adv. Neurol. 80:1999;297-302.
26. Battaglia G., Busceti C.L., Cuomo L., Giorgi F.S., Orzi F., De Blasi A., Nicoletti F., Ruggieri S., Fornai F. Continuous subcutaneous infusion of apomorphine rescue nigrostriatal dopaminergic terminals following MPTP injection in mice. Neuropharmacology. 42:2002;367-373.
27. 2 and 6-hydroxydopamine. Mov. Disord. 13:1998;661-666.
28. Youdim M.B.H., Gassen M., Gross A., Mandel S., Gruenblatt E. Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. J. Neural Transm. Suppl. 58:2000;83-96.
29. Chen Y.-K., Lin H.-C., Liu J.-C., Wan F.-J. Potent, hydroxyl radical-scavenging effect of apomorphine with iron and dopamine perfusion in rat striatum. Brain Res. 896:2001;165-168.
30. Meister A. Glutathione metabolism. Methods Enzymol. 251:1995;3-7.
31. Dormer U.H., Westwater J., Stephen D.W.S., Jamieson D.J. Oxidant regulation of the Saccharomyces cerevisiae GSH1 gene. Biochim. Biophys. Acta. 1576:2002;23-29.
32. 2 sensing through oxidative of the Yap1p transcription factor. EMBO J. 19:2000;5157-5166.
33. Lee J., Godon C., Lagniel G., Spector D., Garin J., Laberre J., Toledano M.B. Yap1p and Skn7 control two specialized oxidative stress response regulons in yeast. J. Biol. Chem. 274:1999;16040-16046.
34. Izawa S., Inoue Y., Kimura A. Importance of catalase in the adaptive response to hydrogen peroxide: analysis of acatalasaemic Saccharomyces cerevisiae. Biochem. J. 320:1996;61-67.
35. Srinivasan C., Liba A., Imlay J.A., Valentine J.S., Gralla E.B. Yeast lacking superoxide dismutase(s) show elevated levels of "free iron" as measured by whole cell electron paramagnetic resonance. J. Biol. Chem. 275:2000;29187-29192.
36. Park J.I., Grant C.M., Davies M.J., Dawes I.W. The cytoplasmic Cu, Zn superoxide dismutase of Saccharomyces cerevisiae is required for resistance to freeze-thaw stress. J. Biol. Chem. 273:1998;22921-22928.